The information you provide to the chat will be collected and recorded to improve your experience and for quality assurance. Please read our privacy policy to see how we are storing and protecting your data.
How can we help you today?
We're proud to receive a 2025 CDMO Leadership Award in the “Small Molecule Dosage Form - Global" category.
Search Patheon
Recent searches
Clear History
Suggestions
All Results
Recent searches
Clear History
Suggestions
All Results
Search
US | EN
Biologics, or therapeutics derived from living organisms, are classified as large molecule drugs. Despite their inherent complexity in development and manufacturing, biologics are increasingly used to treat and prevent flare-ups of diseases like cancers, Crohn's disease, multiple sclerosis, and cystic fibrosis. Their incredible ability to manage and reduce systemic and gastrointestinal inflammation makes them a transformational asset in modern medicine.
Thermo Fisher Scientific has industry-leading expertise in the biologics space, having contributed to over 240 biologics programs. The challenges, risks, and costs of bringing complex large molecules to market are substantial, making competitive advantage challenging to achieve. With 20 years of experience, Thermo Fisher Scientific provides flexible, end-to-end solutions and expertise in development and manufacturing, supported by advanced technical capabilities.
Download our fact sheet for an overview of Thermo Fisher Scientific’s CDMO services and solutions specifically for biologics.
